Peter French
Dr Peter French is a scientist with extensive experience in both basic and clinical medical research and in the biotechnology industry in Australia and the USA. He has over 40 years’ experience in the field of cell and molecular biology, and has published extensively in the areas of oncology, immunology, microbiology and neuroscience.
He has post-graduate qualifications (MSc, PhD) in cell and molecular biology and he holds an MBA in technology management with a track record of successful business creation and capital raising, and growth and strategic leadership of private and public biotechnology, diagnostic and medical devices companies in Australia and in the United States. He is extensively networked in the biotechnology and life sciences community in Australia. He has served as both an executive and non-executive director on Boards of several public and private companies since 2003. Highlights of his biotechnology company career include: the founder of cord blood company Cryosite Limited; the Managing Director of ASX-listed Probiomics Limited, a company involved in developing, manufacturing and launching probiotic based products, and the Managing Director of NASDAQ- and ASX-listed gene therapy company Benitec Biopharma Limited. He is currently the Chief Scientific Officer at BARD1 Life Sciences Limited. BARD1 sells EXo-NET™, the next generation exosome isolation technology. Visit www.exo-net.com.
Peter is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of New South Wales. He is an Adjunct Senior Lecturer at UNSW and an Honorary Fellow at Macquarie University. Peter was awarded the title of “Innovator of Influence, 2015” from the Australian Science and Innovation Forum in 2015. In 2019 he received the University of Sydney’s Faculty of Science Alumni Award for Innovation and Entrepreneurship.
Abstracts this author is presenting: